BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Update

BiomX Inc. (NYSEAMERICAN:PHGE) saw a significant increase in short interest in August. As of August 31st, there was short interest totaling 623,734 shares, an increase of 83.3% from the August 15th total of 340,328 shares. Approximately 2.3% of the shares of the company are short sold. Based on an average trading volume of 1,058,843 shares, the days-to-cover ratio is currently 0.6 days.

BiomX Stock Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 0.24 and a quick ratio of 0.24. BiomX has a twelve month low of $1.19 and a twelve month high of $122.93. The firm has a market capitalization of $4.94 million, a P/E ratio of -0.58 and a beta of 1.33. The firm has a 50-day moving average of $1.74 and a 200 day moving average of $15.01.

BiomX (NYSEAMERICAN:PHGE) last announced its earnings results on Wednesday, August 19th. The company reported ($3.70) EPS for the quarter. The business had revenue of $0.33 million during the quarter. Equities research analysts predict that BiomX will post -58.5 earnings per share for the current fiscal year.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.